Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Software, Service), Method (DNA Methylation), Technique (NGS, PCR & qPCR), Application (Oncology, Immunology), End User & Region - Global Forecast to 2027
Updated on : June 26, 2023
The global epigenetics market in terms of revenue was estimated to be worth $1.7 billion in 2022 and is poised to reach $3.9 billion by 2027, growing at a CAGR of 18.1% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth factors of the market includes, epigenetic enzymes gaining traction in drug discovery & development, rising investments, funds, and grants for epigenetics research, and declining costs of genome sequencing. Increase in the use of epigenetics in non-oncology applications is anticipated to offer profitable opportunities for market expansion. Limited applications of epigenomic data in toxicology and challenges associated with epigenetic editing may hinder the market growth.
To know about the assumptions considered for the study, Request for Free Sample Report
Epigenetics Market Dynamics
Driver: Epigenetic enzymes gaining traction in drug discovery & development
Epigenetic drug discovery and development programs have been gaining traction recently due to large-scale investments and a growing focus on developing novel strategies to reverse epigenetic and transcriptional abnormalities. Epigenetic targets have emerged as the most promising classes of druggable targets. These targets have several research implications, including metabolic, oncology, neurology, inflammatory, and cardiovascular disorders.
Restraint: Limited applications of epigenomic data in toxicology
Toxicology has seen the limited application of epigenomic data; an incomplete understanding of epigenomic variability has led to restricted knowledge on risk assessment across different tissue types and populations. This requires developing new solutions to ensure a comprehensive understanding of epigenetic mechanisms resulting in detailed epigenomic variation mapping. A key obstacle to the application of epigenomic analysis in toxicology is the lack of identification and consensus on a normal epigenome for all tissue and cell types.
The kits & reagents segment dominated the epigenetics industry
Based on product & service, the epigenetics market is segmented into kits & reagents, enzymes, instruments and accessories, software, and service. Kits & reagents segment has generated highest revenue share in the market attributed to the increasing development of easy-to-use, affordable, and advanced epigenetics kits & reagents. This is further propelled by the exponential increase in the number of epigenetics research studies over the years. The kits & reagents are further segmented into antibodies, ChiP-seq kits, bisulfite conversion kits, whole genome amplification kits, 5-hmC and 5-mC analysis kits, histones, and other kits & reagents. The software segment is expected to grow with the highest CAGR during the forecast period. Demand for software solutions has witnessed a significant increase in the epigenetics sequencing market space, epigenetics software solutions assist in the analysis of epigenetic modifications that are complex in nature.
Histone modifications is one of the lucrative segments in the epigenetics industry, expected to grow at a high rate during the forecast period
Based on method, the epigenetics market is segmented into DNA methylation, histone modifications, and other methods. Different types of histone modifications are currently put to use in epigenetics studies, which include, ubiquitination, acetylation, citrullination, methylation, and phosphorylation. Research activities focusing on understanding the role of histone modifications in oncology as well non-oncology applications is expected to supplement the segment growth through the forecast period. DNA methylation represents the largest market share in 2021, increasing research on DNA methylation in non-oncology applications is expected to drive the segment growth.
NGS technique accounted for the largest share in the epigenetics industry
Based on technique, the epigenetics market is segmented into NGS, PCR & qPCR, mass, spectrometry, sonication, and other techniques. Increase in demand for NGS platforms among research professionals to obtain clinically insightful and comprehensive datasets has contributed to the highest revenue generated by NGS segment in the market for the year 2021. Additionally, NGS solutions are gaining traction across mutational and epigenetic research activities, due their ability to sequence epigenomes rapidly. PCR and qPCR segment is expected to witness a rapid growth, registering the highest CAGR during the forecast period. Technological advancements in this market space is expected to propel the segment growth further.
Cardiovascular diseases application segment is expected to grow with the highest CAGR from 2020 to 2027 in the epigenetics industry
Based on applications, the epigenetics market is segmented into oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, and other applications. The role of epigenetics in understanding the etiology of CVDs is growing; research into treatment strategies for these diseases is expected to propel the adoption of epigenetics products. In October 2021, a research article was published on the significance of DNA methylation signatures in coronary heart disease (CHD). The study assessed the association between iCHD (incident CHD) and DNA methylation levels in the genome. This study concluded that the advent of epigenome-wide technologies had provided research professionals an opportunity to add study iCHD at an epigenetic level. Oncology applications dominated the market in 2021, attributed to the opportunities offered by epigenetic processes such as histone modification and DNA methylation to develop novel cancer therapeutic strategies.
Academic & research institutes have emerged as the dominant segment in the epigenetics industry
Based on end users, the epigenetics market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics. Increase in adoption of epigenetics products across government research institutions and university laboratories is the key revenue contributor to the academic & research institutes segment. Pharmaceutical & biotechnology companies segment is anticipated to grow at the fastest pace during the forecast period. Start-ups/SMEs are investing in the market space to design innovative therapeutic strategies. In November 2021, a startup, Chroma Medicine, announced plans to develop epigenetic editors with the ability to alter how genes create proteins. This startup company is funded by Newpath Partners and Atlas Venture, among other investors, with a total of USD 125 million granted collectively. The company plans to employ gene-editing tools to develop drugs that can alter the epigenome, which serves as a novel approach for treating inherited diseases.
North America was the largest regional segment for epigenetics industry
Geographically, the epigenetics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North American market ranked the highest in terms of revenue, whereas Asia Pacific has emerged as the fastest growing regional market for epigenetics. US market is the key revenue contributor to North America epigenetics industry, this region harbors various leading product & service providers including, Pacific Biosciences (US), Thermo Fisher Scientific (US), and Illumina, Inc. (US). The lucrative growth registered by the Asia Pacific epigenetics industry is attributed to the improving healthcare infrastructure in the developing economies, which is set to open new avenues for business expansion for regional key market players.
To know about the assumptions considered for the study, download the pdf brochure
Key players in the epigenetics market include Thermo Fisher Scientific (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories (US), Promega Corporation (US), PerkinElmer (US), Qiagen (Germany), New England Biolabs (US), Zymo Research Corporation (US), Diagenode (Germany), and F. Hoffmann-La Roche Ltd (Switzerland).
Scope of the Epigenetics Industry
|
Report Metric |
Details |
|
Market Revenue in 2022 |
$1.7 billion |
|
Projected Revenue by 2027 |
$3.9 billion |
|
Revenue Rate |
Poised to grow at a CAGR of 18.1% |
|
Market Driver |
Epigenetic enzymes gaining traction in drug discovery & development |
|
Market Opportunity |
Use of epigenetics in non-oncology applications |
This study categorizes the global epigenetics market to forecast revenue and analyze trends in each of the following submarkets:
By Product & Service
-
Kits & Reagents
- Antibodies
- ChiP-seq Kits
- Bisulfite Conversion Kits
- Whole Genome Amplification Kits
- 5-hmC and 5-mC Analysis Kits
- Histones
- Other Kits & Reagents
-
Enzymes
- DNA-modifying Enzymes
- Protein-modifying Enzymes
- Other Enzymes
- Instruments and Accessories
- Software
- Service
By Method
- DNA Methylation
- Histone Modifications
- Other Methods
By Technique
- NGS
- PCR & qPCR
- Mass Spectrometry
- Sonication
- Other Techniques
By Application
- Oncology
- Metabolic Diseases
- Immunology
- Developmental Biology
- Cardiovascular Diseases
- Other Applications
By End User
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Hospitals & Clinics
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- France
- UK
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Recent Developments of Epigenetics Industry
- In 2022, PacBio introduced DNA methylation capabilities via its product line, Sequel, in the US. Introducing this feature to the Sequel systems is expected to extend the accessibility of epigenomes via HiFi sequencing developed by the company.
- In 2021, Proteintech Group is engaged in manufacturing nanobodies, antibodies, and recombinant proteins, has extended its collaboration with Active Motif.
- In 2019, New England BioLabs launched an alternative to bisulfite sequencing, NEBNext Enzymatic Methyl-seq (EM-seq), in the US. This is an enzyme-based product for methylation analysis.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global epigenetics market?
The global epigenetics market boasts a total revenue value of $3.9 billion by 2027.
What is the estimated growth rate (CAGR) of the global epigenetics market?
The global market for epigenetics has an estimated compound annual growth rate (CAGR) of 18.1% and a revenue size in the region of $1.7 billion in 2022.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 34)
1.1 OBJECTIVES OF THE STUDY
1.2 EPIGENETICS MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 EPIGENETICS MARKET
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 38)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 GLOBAL MARKET: BREAKDOWN OF PRIMARIES
2.2 EPIGENETICS MARKET SIZE ESTIMATION
FIGURE 4 EPIGENETICS MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF EPIGENETICS IN THE MARKET
FIGURE 5 EPIGENETICS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 7 GLOBAL EPIGENETICS: CAGR PROJECTIONS, 2022–2027
FIGURE 8 GLOBAL EPIGENETICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 INSIGHTS FROM PRIMARIES
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 49)
FIGURE 12 EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2027
FIGURE 13 EPIGENETICS MARKET, BY METHOD, 2021 VS. 2027
FIGURE 14 EPIGENETICS MARKET, BY TECHNIQUE, 2021 VS. 2027
FIGURE 15 EPIGENETICS MARKET, BY APPLICATION, 2021 VS. 2027
FIGURE 16 EPIGENETICS MARKET, BY END USER, 2021 VS. 2027
FIGURE 17 GEOGRAPHICAL SNAPSHOT: GLOBAL EPIGENETICS MARKET
4 PREMIUM INSIGHTS (Page No. - 53)
4.1 GLOBAL EPIGENETICS MARKET OVERVIEW
FIGURE 18 GROWING USE OF EPIGENETIC ENZYMES IN DRUG DISCOVERY & DEVELOPMENT TO SUPPORT MARKET GROWTH
4.2 NORTH AMERICA: EPIGENETICS MARKET SHARE, BY PRODUCT & SERVICE AND COUNTRY (2021)
FIGURE 19 KITS & REAGENTS ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2021
4.3 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD, 2021 VS. 2027
FIGURE 20 DNA METHYLATION TO DOMINATE THE NORTH AMERICAN MARKET TILL 2027
5 MARKET OVERVIEW (Page No. - 56)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 EPIGENETICS MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Epigenetic enzymes gaining traction in drug discovery & development
TABLE 2 KEY EPIGENETIC ENZYMES FOR REPURPOSING DRUGS
5.2.1.2 Rising investments, funds, and grants for epigenetics research
5.2.1.3 Declining costs of genome sequencing
FIGURE 22 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001–2020
5.2.2 RESTRAINTS
5.2.2.1 Limited applications of epigenomic data in toxicology
5.2.3 OPPORTUNITIES
5.2.3.1 Use of epigenetics in non-oncology applications
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with epigenetic editing
5.2.4.1.1 Off-target effect
5.2.4.1.2 Other challenges
5.3 SCENARIOS ARISING OUT OF UNCERTAINTIES AFFECTING MARKET GROWTH
FIGURE 23 IMPACT OF UNCERTAINTIES ON MARKET GROWTH
5.4 IMPACT OF COVID-19 ON THE GLOBAL EPIGENETICS MARKET
TABLE 3 EPIGENETIC IMPLICATIONS IN CORONAVIRUS INFECTION AND THERAPY
5.5 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 GLOBAL EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF BUYERS
5.5.4 BARGAINING POWER OF SUPPLIERS
5.5.5 DEGREE OF COMPETITION
5.6 ECOSYSTEM ANALYSIS
FIGURE 24 ECOSYSTEM ANALYSIS: GLOBAL MARKET
5.7 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS: GLOBAL MARKET
5.8 SUPPLY CHAIN ANALYSIS
TABLE 5 SUPPLY CHAIN ECOSYSTEM
5.9 REGULATORY ANALYSIS
TABLE 6 KEY REGULATORY AGENCIES
6 EPIGENETICS MARKET, BY PRODUCT & SERVICE (Page No. - 72)
6.1 INTRODUCTION
TABLE 7 EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027
6.2 KITS & REAGENTS
TABLE 8 EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 9 EPIGENETIC KITS & REAGENTS MARKET, BY REGION, 2020–2027
TABLE 10 NORTH AMERICA: EPIGENETIC KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
TABLE 11 EUROPE: EPIGENETIC KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
TABLE 12 ASIA PACIFIC: EPIGENETIC KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
6.2.1 ANTIBODIES
6.2.1.1 Increasing demand for recombinant antibodies for the detection of epigenetic targets propels the segment growth
TABLE 13 ANTIBODIES MARKET, BY REGION, 2020–2027
TABLE 14 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2020–2027
TABLE 15 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2020–2027
TABLE 16 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2020–2027
6.2.2 CHIP-SEQUENCING KITS & REAGENTS
6.2.2.1 Versatile applications of ChIP in epigenetic regulatory systems contribute to the segment’s dominant share
TABLE 17 CHIP-SEQ KITS & REAGENTS MARKET, BY REGION, 2020–2027
TABLE 18 NORTH AMERICA: CHIP-SEQ KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
TABLE 19 EUROPE: CHIP-SEQ KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
TABLE 20 ASIA PACIFIC: CHIP-SEQ KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
6.2.3 BISULFITE CONVERSION KITS & REAGENTS
6.2.3.1 Effectiveness of bisulfite conversion in gene-specific and genome-wide analyses to drive the demand for kits & reagents
TABLE 21 BISULFITE CONVERSION KITS & REAGENTS MARKET, BY REGION, 2020–2027
TABLE 22 NORTH AMERICA: BISULFITE CONVERSION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
TABLE 23 EUROPE: BISULFITE CONVERSION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
TABLE 24 ASIA PACIFIC: BISULFITE CONVERSION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
6.2.4 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS
6.2.4.1 Whole-genome amplification maintains the relative proportions of genes present in the original pool, increasing its preference among researchers
TABLE 25 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY REGION, 2020–2027
TABLE 26 NORTH AMERICA: WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
TABLE 27 EUROPE: WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
TABLE 28 ASIA PACIFIC: WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
6.2.5 5-HMC & 5-MC ANALYSIS KITS & REAGENTS
6.2.5.1 Introduction of unique kits drives market growth
TABLE 29 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET, BY REGION, 2020–2027
TABLE 30 NORTH AMERICA: 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
TABLE 31 EUROPE: 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
TABLE 32 ASIA PACIFIC: 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
6.2.6 HISTONES
6.2.6.1 Importance of chromatin-associated proteins & histones in epigenetic research to drive the segment growth
TABLE 33 HISTONES MARKET, BY REGION, 2020–2027
TABLE 34 NORTH AMERICA: HISTONES MARKET, BY COUNTRY, 2020–2027
TABLE 35 EUROPE: HISTONES MARKET, BY COUNTRY, 2020–2027
TABLE 36 ASIA PACIFIC: HISTONES MARKET, BY COUNTRY, 2020–2027
6.2.7 OTHER KITS & REAGENTS
TABLE 37 OTHER KITS & REAGENTS MARKET, BY REGION, 2020–2027
TABLE 38 NORTH AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
TABLE 39 EUROPE: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
TABLE 40 ASIA PACIFIC: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027
6.3 ENZYMES
TABLE 41 EPIGENETICS MARKET, BY TYPE, 2020–2027
TABLE 42 EPIGENETIC ENZYMES MARKET, BY REGION, 2020–2027
TABLE 43 NORTH AMERICA: EPIGENETIC ENZYMES MARKET, BY COUNTRY, 2020–2027
TABLE 44 EUROPE: EPIGENETIC ENZYMES MARKET, BY COUNTRY, 2020–2027
TABLE 45 ASIA PACIFIC: EPIGENETIC ENZYMES MARKET, BY COUNTRY, 2020–2027
6.3.1 DNA-MODIFYING ENZYMES
6.3.1.1 Growing applications of DNA methylation to contribute to the segment’s dominant share
TABLE 46 DNA-MODIFYING ENZYMES MARKET, BY REGION, 2020–2027
TABLE 47 NORTH AMERICA: DNA-MODIFYING ENZYMES MARKET, BY COUNTRY, 2020–2027
TABLE 48 EUROPE: DNA-MODIFYING ENZYMES MARKET, BY COUNTRY, 2020–2027
TABLE 49 ASIA PACIFIC: DNA-MODIFYING ENZYMES MARKET, BY COUNTRY, 2020–2027
6.3.2 PROTEIN-MODIFYING ENZYMES
6.3.2.1 Increasing pipeline of epigenetics-based drugs targeting histone-modifying enzymes to drive the segment growth
TABLE 50 PROTEIN-MODIFYING ENZYMES MARKET, BY REGION, 2020–2027
TABLE 51 NORTH AMERICA: PROTEIN-MODIFYING ENZYMES MARKET, BY COUNTRY, 2020–2027
TABLE 52 EUROPE: PROTEIN-MODIFYING ENZYMES MARKET, BY COUNTRY, 2020–2027
TABLE 53 ASIA PACIFIC: PROTEIN-MODIFYING ENZYMES MARKET, BY COUNTRY, 2020–2027
6.3.3 OTHER ENZYMES
TABLE 54 OTHER ENZYMES MARKET, BY REGION, 2020–2027
TABLE 55 NORTH AMERICA: OTHER ENZYMES MARKET, BY COUNTRY, 2020–2027
TABLE 56 EUROPE: OTHER ENZYMES MARKET, BY COUNTRY, 2020–2027
TABLE 57 ASIA PACIFIC: OTHER ENZYMES MARKET, BY COUNTRY, 2020–2027
6.4 INSTRUMENTS & ACCESSORIES
6.4.1 WIDE USAGE OF NGS INSTRUMENTS AND SONICATORS TO CONTRIBUTE TO THE SEGMENT REVENUE
TABLE 58 EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET, BY REGION, 2020–2027
TABLE 59 NORTH AMERICA: EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET, BY COUNTRY, 2020–2027
TABLE 60 EUROPE: EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET, BY COUNTRY, 2020–2027
TABLE 61 ASIA PACIFIC: EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET, BY COUNTRY, 2020–2027
6.5 SOFTWARE
6.5.1 DEVELOPMENT OF VIABLE SOFTWARE SOLUTIONS FOR DNA METHYLATION, CHROMATIN, AND RNA ANALYSIS TO PROPEL SEGMENT GROWTH
TABLE 62 EPIGENETIC SOFTWARE MARKET, BY REGION, 2020–2027
TABLE 63 NORTH AMERICA: EPIGENETIC SOFTWARE MARKET, BY COUNTRY, 2020–2027
TABLE 64 EUROPE: EPIGENETIC SOFTWARE MARKET, BY COUNTRY, 2020–2027
TABLE 65 ASIA PACIFIC: EPIGENETIC SOFTWARE MARKET, BY COUNTRY, 2020–2027
6.6 SERVICES
6.6.1 EXPANDING POOL OF PROVIDERS TO DRIVE THE SERVICES SEGMENT
TABLE 66 EPIGENETIC SERVICES MARKET, BY REGION, 2020–2027
TABLE 67 NORTH AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2020–2027
TABLE 68 EUROPE: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2020–2027
TABLE 69 ASIA PACIFIC: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2020–2027
7 EPIGENETICS MARKET, BY METHOD (Page No. - 100)
7.1 INTRODUCTION
TABLE 70 MARKET, BY METHOD, 2020–2027
7.2 DNA METHYLATION
7.2.1 DNA METHYLATION TO DOMINATE THE METHODS MARKET TILL 2027
TABLE 71 EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2020–2027
TABLE 72 NORTH AMERICA: MARKET FOR DNA METHYLATION, BY COUNTRY, 2020–2027
TABLE 73 EUROPE: MARKET FOR DNA METHYLATION, BY COUNTRY, 2020–2027
TABLE 74 ASIA PACIFIC: EPIGENETICS INDUSTRY FOR DNA METHYLATION, BY COUNTRY, 2020–2027
7.3 HISTONE MODIFICATIONS
7.3.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE SEGMENT GROWTH
TABLE 75 COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS
TABLE 76 GLOBAL MARKET FOR HISTONE MODIFICATIONS, BY REGION, 2020–2027
TABLE 77 NORTH AMERICA: MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2020–2027
TABLE 78 EUROPE: MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2020–2027
TABLE 79 ASIA PACIFIC: EPIGENETICS INDUSTRY FOR HISTONE MODIFICATIONS, BY COUNTRY, 2020–2027
7.4 OTHER METHODS
TABLE 80 GLOBAL EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2020–2027
TABLE 81 NORTH AMERICA: MARKET FOR OTHER METHODS, BY COUNTRY, 2020–2027
TABLE 82 EUROPE: MARKET FOR OTHER METHODS, BY COUNTRY, 2020–2027
TABLE 83 ASIA PACIFIC: MARKET FOR OTHER METHODS, BY COUNTRY, 2020–2027
8 EPIGENETICS MARKET, BY TECHNIQUE (Page No. - 108)
8.1 INTRODUCTION
TABLE 84 EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027
8.2 NGS
8.2.1 NGS OFFERS COMPREHENSIVE EPIGENETIC PROFILES, WHICH DRIVES ADOPTION
TABLE 85 GLOBAL EPIGENETICS MARKET FOR NGS, BY REGION, 2020–2027
TABLE 86 NORTH AMERICA: MARKET FOR NGS, BY COUNTRY, 2020–2027
TABLE 87 EUROPE: MARKET FOR NGS, BY COUNTRY, 2020–2027
TABLE 88 ASIA PACIFIC: EPIGENETICS INDUSTRY FOR NGS, BY COUNTRY, 2020–2027
8.3 PCR & QPCR
8.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO PROPEL THE SEGMENT GROWTH
TABLE 89 GLOBAL EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2020–2027
TABLE 90 NORTH AMERICA: MARKET FOR PCR & QPCR, BY COUNTRY, 2020–2027
TABLE 91 EUROPE: MARKET FOR PCR & QPCR, BY COUNTRY, 2020–2027
TABLE 92 ASIA PACIFIC: MARKET FOR PCR & QPCR, BY COUNTRY, 2020–2027
8.4 MASS SPECTROMETRY
8.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN HISTONE EPIGENETICS STUDIES TO DRIVE THE SEGMENT GROWTH
TABLE 93 GLOBAL EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2020–2027
TABLE 94 NORTH AMERICA: MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2020–2027
TABLE 95 EUROPE: MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2020–2027
TABLE 96 ASIA PACIFIC: EPIGENETICS INDUSTRY FOR MASS SPECTROMETRY, BY COUNTRY, 2020–2027
8.5 SONICATION
8.5.1 ADVENT OF IMPROVED HIGH-THROUGHPUT SONICATION TO PROPEL ITS ADOPTION IN EPIGENETICS STUDIES
TABLE 97 GLOBAL EPIGENETICS MARKET FOR SONICATION, BY REGION, 2020–2027
TABLE 98 NORTH AMERICA: MARKET FOR SONICATION, BY COUNTRY, 2020–2027
TABLE 99 EUROPE: MARKET FOR SONICATION, BY COUNTRY, 2020–2027
TABLE 100 ASIA PACIFIC: MARKET FOR SONICATION, BY COUNTRY, 2020–2027
8.6 OTHER TECHNIQUES
TABLE 101 GLOBAL EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY REGION, 2020–2027
TABLE 102 NORTH AMERICA: MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2020–2027
TABLE 103 EUROPE: MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2020–2027
TABLE 104 ASIA PACIFIC: EPIGENETICS INDUSTRY FOR OTHER TECHNIQUES, BY COUNTRY, 2020–2027
9 EPIGENETICS MARKET, BY APPLICATION (Page No. - 119)
9.1 INTRODUCTION
TABLE 105 EPIGENETICS MARKET, BY APPLICATION, 2020–2027
9.2 ONCOLOGY
9.2.1 ONCOLOGY TO HOLD LARGEST SHARE OF THE APPLICATIONS SEGMENT TILL 2027
TABLE 106 EPIGENOME-TARGETING CANCER DRUGS APPROVED OR IN CLINICAL TRIALS
TABLE 107 EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2020–2027
TABLE 108 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027
TABLE 109 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027
TABLE 110 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027
9.3 METABOLIC DISEASES
9.3.1 EMERGING ROLE OF DNA METHYLATION IN DIABETES MANAGEMENT TO DRIVE THE SEGMENT GROWTH
TABLE 111 EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 2020–2027
TABLE 112 NORTH AMERICA: MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027
TABLE 113 EUROPE: MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027
TABLE 114 ASIA PACIFIC: MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027
9.4 IMMUNOLOGY
9.4.1 RISING DEMAND FOR EPIGENETICS PRODUCTS IN TUMOR AND TRANSPLANTATION IMMUNOLOGY TO DRIVE SEGMENT’S GROWTH
TABLE 115 EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION, 2020–2027
TABLE 116 NORTH AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027
TABLE 117 EUROPE: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027
TABLE 118 ASIA PACIFIC: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027
9.5 DEVELOPMENTAL BIOLOGY
9.5.1 GROWING R&D IN DEVELOPMENTAL BIOLOGY TO PROPEL THE SEGMENT’S GROWTH
TABLE 119 GLOBAL EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2020–2027
TABLE 120 NORTH AMERICA: MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2020–2027
TABLE 121 EUROPE: MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2020–2027
TABLE 122 ASIA PACIFIC: MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2020–2027
9.6 CARDIOVASCULAR DISEASES
9.6.1 EMERGING ROLE OF EPIGENETICS IN UNDERSTANDING THE ETIOLOGY OF CARDIOVASCULAR DISEASES TO PROPEL PRODUCT ADOPTION
TABLE 123 EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027
TABLE 124 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027
TABLE 125 EUROPE: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027
TABLE 126 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027
9.7 OTHER APPLICATIONS
TABLE 127 EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027
TABLE 128 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027
TABLE 129 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027
TABLE 130 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027
10 EPIGENETICS MARKET, BY END USER (Page No. - 133)
10.1 INTRODUCTION
TABLE 131 GLOBAL MARKET, BY END USER, 2020–2027
10.2 ACADEMIC & RESEARCH INSTITUTES
10.2.1 HIGH SHARE ATTRIBUTED TO RISING COLLABORATIONS AMONG RESEARCH INSTITUTES AND DEMAND FOR CANCER EPIGENETICS
TABLE 132 GLOBAL EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027
TABLE 133 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027
TABLE 134 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027
TABLE 135 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3.1 HIGH NUMBER OF CLINICAL TRIALS FOR EPIGENETICS-BASED DRUGS TO DRIVE THE SEGMENT GROWTH
TABLE 136 EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027
TABLE 137 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027
TABLE 138 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027
TABLE 139 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027
10.4 HOSPITALS & CLINICS
10.4.1 RISING IMPORTANCE OF DNA METHYLATION MEASUREMENTS TO DRIVE SEGMENT GROWTH
TABLE 140 EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027
TABLE 141 NORTH AMERICA: MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027
TABLE 142 EUROPE: MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027
TABLE 143 ASIA PACIFIC: MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027
11 EPIGENETICS MARKET, BY REGION (Page No. - 141)
11.1 INTRODUCTION
TABLE 144 EPIGENETICS MARKET, BY REGION, 2020–2027
11.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT
TABLE 145 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027
TABLE 146 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2027
TABLE 147 NORTH AMERICA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 148 NORTH AMERICA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027
TABLE 149 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD, 2020–2027
TABLE 150 NORTH AMERICA: MARKET, BY TECHNIQUE, 2020–2027
TABLE 151 NORTH AMERICA: EPIGENETICS INDUSTRY, BY APPLICATION, 2020–2027
TABLE 152 NORTH AMERICA: EPIGENETICS MARKET, BY END USER, 2020–2027
11.2.1 US
11.2.1.1 A strong network of well-established epigenetic product manufacturers is the key growth contributor
TABLE 153 US: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027
TABLE 154 US: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 155 US: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027
TABLE 156 US: EPIGENETICS MARKET, BY METHOD, 2020–2027
TABLE 157 US: MARKET, BY TECHNIQUE, 2020–2027
TABLE 158 US: EPIGENETICS INDUSTRY, BY APPLICATION, 2020–2027
TABLE 159 US: EPIGENETICS MARKET, BY END USER, 2020–2027
11.2.2 CANADA
11.2.2.1 Government initiatives to boost epigenetics research contribute to the market growth
TABLE 160 CANADA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027
TABLE 161 CANADA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 162 CANADA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027
TABLE 163 CANADA: EPIGENETICS MARKET, BY METHOD, 2020–2027
TABLE 164 CANADA: MARKET, BY TECHNIQUE, 2020–2027
TABLE 165 CANADA: MARKET, BY APPLICATION, 2020–2027
TABLE 166 CANADA: EPIGENETICS MARKET, BY END USER, 2020–2027
11.3 EUROPE
TABLE 167 EUROPE: EPIGENETICS MARKET, BY COUNTRY, 2020–2027
TABLE 168 EUROPE: MARKET, BY PRODUCT & SERVICE, 2020–2027
TABLE 169 EUROPE: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 170 EUROPE: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027
TABLE 171 EUROPE: EPIGENETICS MARKET, BY METHOD, 2020–2027
TABLE 172 EUROPE: MARKET, BY TECHNIQUE, 2020–2027
TABLE 173 EUROPE: EPIGENETICS INDUSTRY, BY APPLICATION, 2020–2027
TABLE 174 EUROPE: EPIGENETICS MARKET, BY END USER, 2020–2027
11.3.1 GERMANY
11.3.1.1 Significant investments in the NGS market space in Germany expected to boost the uptake of epigenetics products
TABLE 175 GERMANY: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027
TABLE 176 GERMANY: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 177 GERMANY: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027
TABLE 178 GERMANY: EPIGENETICS MARKET, BY METHOD, 2020–2027
TABLE 179 GERMANY: MARKET, BY TECHNIQUE, 2020–2027
TABLE 180 GERMANY: MARKET, BY APPLICATION, 2020–2027
TABLE 181 GERMANY: EPIGENETICS MARKET, BY END USER, 2020–2027
11.3.2 UK
11.3.2.1 Rising acceptance of genome-based diagnostic techniques to drive the UK epigenetics market
TABLE 182 UK: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027
TABLE 183 UK: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 184 UK: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027
TABLE 185 UK: EPIGENETICS MARKET, BY METHOD, 2020–2027
TABLE 186 UK: MARKET, BY TECHNIQUE, 2020–2027
TABLE 187 UK: EPIGENETICS INDUSTRY, BY APPLICATION, 2020–2027
TABLE 188 UK: EPIGENETICS MARKET, BY END USER, 2020–2027
11.3.3 FRANCE
11.3.3.1 Growing demand for PCR technologies propelled by favorable government initiatives to boost the market growth
TABLE 189 FRANCE: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027
TABLE 190 FRANCE: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 191 FRANCE: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027
TABLE 192 FRANCE: EPIGENETICS MARKET, BY METHOD, 2020–2027
TABLE 193 FRANCE: MARKET, BY TECHNIQUE, 2020–2027
TABLE 194 FRANCE: MARKET, BY APPLICATION, 2020–2027
TABLE 195 FRANCE: EPIGENETICS MARKET, BY END USER, 2020–2027
11.3.4 REST OF EUROPE
TABLE 196 REST OF EUROPE: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027
TABLE 197 REST OF EUROPE: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 198 REST OF EUROPE: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027
TABLE 199 REST OF EUROPE: EPIGENETICS MARKET, BY METHOD, 2020–2027
TABLE 200 REST OF EUROPE: MARKET, BY TECHNIQUE, 2020–2027
TABLE 201 REST OF EUROPE: EPIGENETICS INDUSTRY, BY APPLICATION, 2020–2027
TABLE 202 REST OF EUROPE: EPIGENETICS MARKET, BY END USER, 2020–2027
11.4 ASIA PACIFIC
FIGURE 27 ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT
TABLE 203 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027
TABLE 204 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2020–2027
TABLE 205 ASIA PACIFIC: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 206 ASIA PACIFIC: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027
TABLE 207 ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2020–2027
TABLE 208 ASIA PACIFIC: MARKET, BY TECHNIQUE, 2020–2027
TABLE 209 ASIA PACIFIC: EPIGENETICS INDUSTRY, BY APPLICATION, 2020–2027
TABLE 210 ASIA PACIFIC: EPIGENETICS MARKET, BY END USER, 2020–2027
11.4.1 JAPAN
11.4.1.1 Research-academia collaborations have driven awareness of epigenetics in the country
TABLE 211 JAPAN: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027
TABLE 212 JAPAN: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 213 JAPAN: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027
TABLE 214 JAPAN: EPIGENETICS MARKET, BY METHOD, 2020–2027
TABLE 215 JAPAN: MARKET, BY TECHNIQUE, 2020–2027
TABLE 216 JAPAN: EPIGENETICS INDUSTRY, BY APPLICATION, 2020–2027
TABLE 217 JAPAN: EPIGENETICS MARKET, BY END USER, 2020–2027
11.4.2 CHINA
11.4.2.1 Increasing research on genomics and high demand for personalized medicine to propel the Chinese market
TABLE 218 CHINA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027
TABLE 219 CHINA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 220 CHINA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027
TABLE 221 CHINA: EPIGENETICS MARKET, BY METHOD, 2020–2027
TABLE 222 CHINA: MARKET, BY TECHNIQUE, 2020–2027
TABLE 223 CHINA: EPIGENETICS INDUSTRY, BY APPLICATION, 2020–2027
TABLE 224 CHINA: EPIGENETICS MARKET, BY END USER, 2020–2027
11.4.3 INDIA
11.4.3.1 Activities to strengthen genomics research by expanding the base of biotechnology facilities to drive market growth
TABLE 225 INDIA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027
TABLE 226 INDIA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 227 INDIA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027
TABLE 228 INDIA: EPIGENETICS MARKET, BY METHOD, 2020–2027
TABLE 229 INDIA: MARKET, BY TECHNIQUE, 2020–2027
TABLE 230 INDIA: EPIGENETICS INDUSTRY, BY APPLICATION, 2020–2027
TABLE 231 INDIA: EPIGENETICS MARKET, BY END USER, 2020–2027
11.4.4 REST OF ASIA PACIFIC
TABLE 232 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027
TABLE 233 REST OF ASIA PACIFIC: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 234 REST OF ASIA PACIFIC: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027
TABLE 235 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2020–2027
TABLE 236 REST OF ASIA PACIFIC: MARKET, BY TECHNIQUE, 2020–2027
TABLE 237 REST OF ASIA PACIFIC: EPIGENETICS INDUSTRY, BY APPLICATION, 2020–2027
TABLE 238 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY END USER, 2020–2027
11.5 LATIN AMERICA
11.5.1 ADVANCEMENTS IN EPIGENETIC ANALYSIS AND CHARACTERIZATION TO BOOST THE UPTAKE OF MARKET PRODUCTS
TABLE 239 LATIN AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027
TABLE 240 LATIN AMERICA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 241 LATIN AMERICA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027
TABLE 242 LATIN AMERICA: MARKET, BY METHOD, 2020–2027
TABLE 243 LATIN AMERICA: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027
TABLE 244 LATIN AMERICA: EPIGENETICS INDUSTRY, BY APPLICATION, 2020–2027
TABLE 245 LATIN AMERICA: EPIGENETICS MARKET, BY END USER, 2020–2027
11.6 MIDDLE EAST & AFRICA
11.6.1 RISING FUNDING AND PARTNERSHIPS IN RESEARCH TO BOOST MARKET GROWTH IN THE MIDDLE EAST & AFRICA
TABLE 246 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027
TABLE 247 MIDDLE EAST & AFRICA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027
TABLE 248 MIDDLE EAST & AFRICA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027
TABLE 249 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY METHOD, 2020–2027
TABLE 250 MIDDLE EAST & AFRICA: MARKET, BY TECHNIQUE, 2020–2027
TABLE 251 MIDDLE EAST & AFRICA: EPIGENETICS INDUSTRY, BY APPLICATION, 2020–2027
TABLE 252 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY END USER, 2020–2027
12 COMPETITIVE LANDSCAPE (Page No. - 189)
12.1 INTRODUCTION
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 28 EPIGENETICS MARKET: STRATEGIES ADOPTED
12.3 MARKET SHARE ANALYSIS
FIGURE 29 GLOBAL EPIGENETICS MARKET: MARKET SHARE ANALYSIS OF TOP 5 PLAYERS (2021)
12.4 REVENUE SHARE ANALYSIS (TOP 5 MARKET PLAYERS)
FIGURE 30 REVENUE ANALYSIS FOR KEY COMPANIES OVER THE PAST 2-3 YEARS
12.5 COMPANY EVALUATION QUADRANT (KEY MARKET PLAYERS)
FIGURE 31 GLOBAL EPIGENETICS MARKET: COMPANY EVALUATION MATRIX, 2021
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPETITIVE BENCHMARKING—STARTUPS/SMES
TABLE 253 GLOBAL EPIGENETICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 254 GLOBAL EPIGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [STARTUPS/SMES]
12.6 COMPETITIVE SCENARIO AND TRENDS
12.6.1 PRODUCT LAUNCHES
TABLE 255 GLOBAL EPIGENETICS MARKET: PRODUCT LAUNCHES
12.6.2 DEALS
TABLE 256 GLOBAL EPIGENETICS MARKET: ACQUISITIONS
13 COMPANY PROFILES (Page No. - 197)
13.1 KEY COMPANIES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 THERMO FISHER SCIENTIFIC INC.
TABLE 257 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 32 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
13.1.2 ILLUMINA, INC.
TABLE 258 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 33 ILLUMINA, INC.: COMPANY SNAPSHOT
13.1.3 PACIFIC BIOSCIENCES
TABLE 259 PACBIO: BUSINESS OVERVIEW
FIGURE 34 PACBIO: COMPANY SNAPSHOT
13.1.4 ABCAM PLC.
TABLE 260 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 35 ABCAM PLC: COMPANY SNAPSHOT
13.1.5 MERCK KGAA
TABLE 261 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT
13.1.6 BIO-RAD LABORATORIES, INC.
TABLE 262 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 37 BIO-RAD LABORATORIES: COMPANY SNAPSHOT
13.1.7 ACTIVE MOTIF
TABLE 263 ACTIVE MOTIF: BUSINESS OVERVIEW
13.1.8 NEW ENGLAND BIOLABS
TABLE 264 NEW ENGLAND BIOLABS: BUSINESS OVERVIEW
13.1.9 QIAGEN
TABLE 265 QIAGEN: BUSINESS OVERVIEW
FIGURE 38 QIAGEN: COMPANY SNAPSHOT
13.1.10 ZYMO RESEARCH CORPORATION
TABLE 266 ZYMO RESEARCH CORPORATION: BUSINESS OVERVIEW
13.1.11 PERKINELMER INC.
TABLE 267 PERKINELMER INC.: BUSINESS OVERVIEW
13.1.12 DIAGENODE
TABLE 268 DIAGENODE: BUSINESS OVERVIEW
13.1.13 F. HOFFMANN-LA ROCHE LTD
TABLE 269 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
FIGURE 39 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
13.1.14 PROMEGA CORPORATION
TABLE 270 PROMEGA CORPORATION: BUSINESS OVERVIEW
13.2 OTHER PLAYERS
13.2.1 EPIGENTEK GROUP INC.
13.2.2 EPICYPHER
13.2.3 EVERON LIFE SCIENCES
13.2.4 FIOS GENOMICS
13.2.5 GENOMESCAN
13.2.6 CREATIVE BIOGENE
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX (Page No. - 240)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the epigenetics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the epigenetics market. The secondary sources used for this study include World Health Organization (WHO), World Intellectual Property Organization (WIPO), International Union of Biochemistry and Molecular Biology (IUBMB), National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), Centers for Disease Control and Prevention (CDC), American Cancer Society (ACS), American Society for Biochemistry and Molecular Biology (ASBMB), Canadian Society for Molecular Biosciences (CSMB), National Institute of Environmental Health Sciences, Canadian Institutes of Health Research, and Genome Canada, Annual Reports, SEC Filings, Investor Presentations, Press Releases, Conferences, Journals, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the epigenetics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the epigenetics business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the global epigenetics market based on the product & service, method, technique, application, end user and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
- To strategically analyse micromarkets with respect to individual growth trends, future prospects, and contributions to the overall epigenetics market
- To analyse opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the epigenetics market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Company Information
- An additional five company profiles
Top 10 companies in the transcriptional analysis market, ranked by revenue and market share
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- QIAGEN N.V.
- PerkinElmer, Inc.
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche Ltd.
- Fluidigm Corporation
- NanoString Technologies, Inc.
- Pacific Biosciences of California, Inc.
Regional distribution of top 10 companies in the transcriptional analysis market
Illumina, Inc.: Illumina is headquartered in San Diego, California, USA, and has operations and customers in North America, Europe, Asia Pacific, and other regions. The company has manufacturing facilities in the United States, Singapore, and the United Kingdom.
Thermo Fisher Scientific Inc.: Thermo Fisher Scientific is based in Waltham, Massachusetts, USA, and has a global presence with customers in North America, Europe, Asia Pacific, and other regions. The company has manufacturing facilities in various locations around the world, including the United States, Europe, and Asia.
Agilent Technologies, Inc.: Agilent Technologies is based in Santa Clara, California, USA, and has a global presence with customers in North America, Europe, Asia Pacific, and other regions. The company has manufacturing facilities in various locations around the world, including the United States, Europe, and Asia.
QIAGEN N.V.: QIAGEN is headquartered in Venlo, Netherlands, and has a global presence with customers in North America, Europe, Asia Pacific, and other regions. The company has manufacturing facilities in various locations around the world, including the United States, Germany, and China.
PerkinElmer, Inc.: PerkinElmer is based in Waltham, Massachusetts, USA, and has a global presence with customers in North America, Europe, Asia Pacific, and other regions. The company has manufacturing facilities in various locations around the world, including the United States, Europe, and Asia.
Bio-Rad Laboratories, Inc.: Bio-Rad Laboratories is based in Hercules, California, USA, and has a global presence with customers in North America, Europe, Asia Pacific, and other regions. The company has manufacturing facilities in various locations around the world, including the United States, Europe, and Asia.
F. Hoffmann-La Roche Ltd.: Roche is headquartered in Basel, Switzerland, and has a global presence with customers in North America, Europe, Asia Pacific, and other regions. The company has manufacturing facilities in various locations around the world, including Switzerland, the United States, and Germany.
Fluidigm Corporation: Fluidigm is based in South San Francisco, California, USA, and has a global presence with customers in North America, Europe, Asia Pacific, and other regions. The company has manufacturing facilities in various locations around the world, including the United States and Singapore.
NanoString Technologies, Inc.: NanoString is based in Seattle, Washington, USA, and has a global presence with customers in North America, Europe, Asia Pacific, and other regions. The company has manufacturing facilities in the United States.
Pacific Biosciences of California, Inc.: Pacific Biosciences is based in Menlo Park, California, USA, and has a global presence with customers in North America, Europe, Asia Pacific, and other regions. The company has manufacturing facilities in the United States.
Potential growth opportunities for the transcriptional analysis market
Development of personalized medicine: Transcriptional analysis can help in the development of personalized medicine by identifying biomarkers and genetic mutations associated with various diseases. As personalized medicine becomes more common, the demand for transcriptional analysis tools is likely to increase.
Advancements in genomics research: As genomics research continues to advance, there will be an increased demand for transcriptional analysis tools that can help researchers to better understand gene expression and regulation.
Increased focus on drug discovery and development: With the rising cost of drug development, pharmaceutical companies are looking for ways to streamline the process. Transcriptional analysis can help to identify drug targets and biomarkers, which can speed up drug discovery and development.
Expansion of oncology research: With cancer being a leading cause of death worldwide, there is a growing demand for better cancer treatments. Transcriptional analysis can help to identify new biomarkers and drug targets for cancer, leading to more effective treatments.
Integration with other technologies: Transcriptional analysis can be combined with other technologies such as CRISPR, synthetic biology, and artificial intelligence to enhance research capabilities and develop novel therapies.
Increasing demand for RNA sequencing: RNA sequencing is becoming more common as a method for gene expression analysis. The demand for transcriptional analysis tools that can handle large amounts of RNA sequencing data is likely to increase.
Emergence of liquid biopsy: Liquid biopsy is a non-invasive method for detecting cancer by analyzing blood samples. Transcriptional analysis can be used to analyze gene expression in these samples, leading to earlier detection and more effective treatment.
Potential threats/restraints that may impact the transcriptional analysis market in the future
Complexity of data: With the increasing volume and complexity of data generated from transcriptional analysis, there may be challenges in data management, processing, and interpretation.
Regulatory challenges: The transcriptional analysis market is subject to regulatory oversight, and changes in regulations or guidelines may impact the development and commercialization of new products.
Competition: The market is highly competitive, and new entrants may struggle to compete with established players with significant market share.
High cost of technology: The cost of transcriptional analysis technology and equipment can be high, which may limit adoption by smaller organizations or research groups.
Lack of standardization: There is currently no standardization in the field of transcriptional analysis, which can make it difficult to compare results across different studies or organizations.
Data privacy and security concerns: As with any data-driven industry, there are concerns about data privacy and security, particularly with the increasing use of cloud-based platforms.
Ethical considerations: Transcriptional analysis has the potential to reveal sensitive information about individuals or populations, which raises ethical considerations around consent and data usage.
Limited understanding of the underlying biology: Despite significant progress in the field, there is still much to learn about the underlying biology of transcriptional regulation, which may limit the ability to fully leverage the potential of the technology.
It's worth noting that some of these threats/restraints may also present opportunities for innovation and growth, as companies work to address these challenges and develop new solutions.
Future use cases of transcriptional analysis with commentary on their market potential, adoption, and potential risks
Personalized medicine: Transcriptional analysis can be used to develop personalized treatment plans for patients based on their unique genetic profiles. This has the potential to improve patient outcomes and reduce healthcare costs. However, the adoption of personalized medicine is still limited due to regulatory and reimbursement challenges.
Drug development: Transcriptional analysis can be used to identify potential drug targets and assess the safety and efficacy of new drugs. This can accelerate the drug development process and reduce the cost of bringing new drugs to market. However, the high cost of transcriptional analysis and the complexity of the data generated are potential challenges.
Agriculture: Transcriptional analysis can be used to improve crop yields, increase resistance to pests and diseases, and develop new plant varieties. This has the potential to improve food security and reduce the environmental impact of agriculture. However, there may be regulatory and ethical concerns around the use of genetically modified crops.
Environmental monitoring: Transcriptional analysis can be used to monitor environmental pollutants and assess the health of ecosystems. This has the potential to improve environmental management and protect public health. However, the accuracy and reliability of transcriptional analysis in complex environmental samples are still being evaluated.
Forensics: Transcriptional analysis can be used to identify suspects in criminal investigations and provide evidence in court. This has the potential to improve the accuracy and reliability of forensic evidence. However, there may be concerns around privacy and the potential misuse of genetic information.
Generating Response ...
Growth opportunities and latent adjacency in Epigenetics Market